183 related articles for article (PubMed ID: 31417958)
1. MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma.
Sgarbura O; Gourgou S; Tosi D; Bakrin N; Bouazza N; Delaine S; De Forges H; Pocard M; Quénet F
Pleura Peritoneum; 2019 Jun; 4(2):20190010. PubMed ID: 31417958
[TBL] [Abstract][Full Text] [Related]
2. PIPAC-OV3: A multicenter, open-label, randomized, two-arm phase III trial of the effect on progression-free survival of cisplatin and doxorubicin as Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) vs. chemotherapy alone in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
Bakrin N; Tempfer C; Scambia G; De Simone M; Gabriel B; Grischke EM; Rau B
Pleura Peritoneum; 2018 Sep; 3(3):20180114. PubMed ID: 30911662
[TBL] [Abstract][Full Text] [Related]
3. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer: a randomized multicenter phase III trial PIPAC VEROne.
Casella F; Bencivenga M; Rosati R; Fumagalli UR; Marrelli D; Pacelli F; Macrì A; Donini A; Torroni L; Pavarana M; De Manzoni G
Pleura Peritoneum; 2022 Sep; 7(3):135-141. PubMed ID: 36159218
[TBL] [Abstract][Full Text] [Related]
4. Pressurized IntraPeritoneal Aerosol Chemotherapy vs. intravenous chemotherapy for unresectable peritoneal metastases secondary to platinum resistant ovarian cancer - study protocol for a randomized control trial.
Somashekhar SP; Ashwin KR; Rauthan A; Rohit KC
Pleura Peritoneum; 2019 Mar; 4(1):20180111. PubMed ID: 31198851
[TBL] [Abstract][Full Text] [Related]
5. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in combination with standard of care chemotherapy in primarily untreated chemo naïve upper gi-adenocarcinomas with peritoneal seeding - a phase II/III trial of the AIO/CAOGI/ACO.
Oliver Goetze T; Al-Batran SE; Pabst U; Reymond M; Tempfer C; Bechstein WO; Bankstahl U; Gockel I; Königsrainer A; Kraus T; Mönig SP; Rau B; Schwarzbach M; Piso P
Pleura Peritoneum; 2018 Jun; 3(2):20180113. PubMed ID: 30911658
[TBL] [Abstract][Full Text] [Related]
6. PIPAC EstoK 01: Pressurized IntraPeritoneal Aerosol Chemotherapy with cisplatin and doxorubicin (PIPAC C/D) in gastric peritoneal metastasis: a randomized and multicenter phase II study.
Eveno C; Jouvin I; Pocard M
Pleura Peritoneum; 2018 Jun; 3(2):20180116. PubMed ID: 30911659
[TBL] [Abstract][Full Text] [Related]
7. Non-resectable Malignant Peritoneal Mesothelioma Treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Plus Systemic Chemotherapy Could Lead to Secondary Complete Cytoreductive Surgery: A Cohort Study.
Kepenekian V; Péron J; You B; Bonnefoy I; Villeneuve L; Alyami M; Bakrin N; Rousset P; Benzerdjeb N; Glehen O
Ann Surg Oncol; 2022 Mar; 29(3):2104-2113. PubMed ID: 34713369
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of oxaliplatin dose escalation via a laparoscopic approach using pressurized aerosol intraperitoneal chemotherapy (PIPOX trial) for nonresectable peritoneal metastases of digestive cancers (stomach, small bowel and colorectal): Rationale and design.
Dumont F; Senellart H; Pein F; Campion L; Glehen O; Goere D; Pocard M; Thibaudeau E
Pleura Peritoneum; 2018 Sep; 3(3):20180120. PubMed ID: 30911664
[TBL] [Abstract][Full Text] [Related]
9. Multicenter dose-escalation Phase I trial of mitomycin C pressurized intraperitoneal aerosolized chemotherapy in combination with systemic chemotherapy for appendiceal and colorectal peritoneal metastases: rationale and design.
Raoof M; Sullivan KM; Frankel PH; Fakih M; Synold TW; Lim D; Woo Y; Paz IB; Fong Y; Thomas RM; Chang S; Eng M; Tinsley R; Whelan RL; Deperalta D; Reymond MA; Jones J; Merchea A; Dellinger TH
Pleura Peritoneum; 2022 Dec; 7(4):169-177. PubMed ID: 36560966
[TBL] [Abstract][Full Text] [Related]
10. Initial experience of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a French hyperthermic intraperitoneal chemotherapy (HIPEC) expert center.
Ceribelli C; Debs T; Chevallier A; Piche MA; Bereder JM
Surg Endosc; 2020 Jun; 34(6):2803-2806. PubMed ID: 32166545
[TBL] [Abstract][Full Text] [Related]
11. Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Alyami M; Mercier F; Siebert M; Bonnot PE; Laplace N; Villeneuve L; Passot G; Glehen O; Bakrin N; Kepenekian V
Eur J Surg Oncol; 2021 Jan; 47(1):128-133. PubMed ID: 31253545
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
de Boer NL; van Kooten JP; Burger JWA; Verhoef C; Aerts JGJV; Madsen EVE
BMJ Open; 2019 May; 9(5):e026779. PubMed ID: 31092657
[TBL] [Abstract][Full Text] [Related]
13. Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma.
Giger-Pabst U; Demtröder C; Falkenstein TA; Ouaissi M; Götze TO; Rezniczek GA; Tempfer CB
BMC Cancer; 2018 Apr; 18(1):442. PubMed ID: 29669524
[TBL] [Abstract][Full Text] [Related]
14. Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis: a phase II study.
Struller F; Horvath P; Solass W; Weinreich FJ; Strumberg D; Kokkalis MK; Fischer I; Meisner C; Königsrainer A; Reymond MA
Ther Adv Med Oncol; 2019; 11():1758835919846402. PubMed ID: 31205501
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of intravenous versus bidirectional chemotherapy after cytoreductive surgery for malignant peritoneal mesothelioma.
Sugarbaker PH
Int J Surg Protoc; 2023 Dec; 27(3):108-117. PubMed ID: 38046900
[TBL] [Abstract][Full Text] [Related]
16. Randomized control trial comparing quality of life of patients with end-stage peritoneal metastasis treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC) and intravenous chemotherapy.
Somashekhar SP; Ashwin KR; Rauthan CA; Rohit KC
Pleura Peritoneum; 2018 Sep; 3(3):20180110. PubMed ID: 30911661
[TBL] [Abstract][Full Text] [Related]
17. Effect of Pressurized Intraperitoneal Aerosol Chemotherapy on the Survival Rate of Patients with Peritoneal Carcinomatosis of Gastric Origin.
Tidadini F; Abba J; Quesada JL; Baudrant M; Bonne A; Foote A; Faucheron JL; Glehen O; Villeneuve L; Arvieux C
J Gastrointest Cancer; 2022 Dec; 53(4):971-979. PubMed ID: 34677795
[TBL] [Abstract][Full Text] [Related]
18. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Oxaliplatin, Cisplatin, and Doxorubicin in Patients with Peritoneal Carcinomatosis: An Open-Label, Single-Arm, Phase II Clinical Trial.
De Simone M; Vaira M; Argenziano M; Berchialla P; Pisacane A; Cinquegrana A; Cavalli R; Borsano A; Robella M
Biomedicines; 2020 Apr; 8(5):. PubMed ID: 32365877
[TBL] [Abstract][Full Text] [Related]
19. Oncological Outcomes After Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in the Treatment of Peritoneal Carcinomatosis.
Tidadini F; Abba J; Quesada JL; Trilling B; Bonne A; Foote A; Faucheron JL; Arvieux C
J Gastrointest Cancer; 2023 Jun; 54(2):632-641. PubMed ID: 35778645
[TBL] [Abstract][Full Text] [Related]
20. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis.
Robella M; Vaira M; De Simone M
World J Surg Oncol; 2016 Apr; 14():128. PubMed ID: 27125996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
